News & Updates

Upgrade Subscription

15 November 2024

CDMOs Acquisitions Industry News

Evotec Divests Halle Manufacturing Site to Monacum Partners

Evotec has divested its chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners, a Munich-based private equity firm. This transaction comes as part of Evotec’s ‘Priority Reset’ initiative launched in April 2024, which aims to foster profitable growth by refining the company’s operational footprint and focusing on its primary growth sectors and core competencies.

Evotec DS in Halle/Westphalia is a specialised CDMO focused on chemical APIs, intermediates, and building blocks, which provides an end-to-end service portfolio, encompassing development to commercial-scale manufacturing. Under the agreement, all business operations and the entire workforce at Evotec DS will transition to Monacum Partners and continue business as DAPIN GmbH (Deutsche API & Intermediates). Financial terms of the transaction were not disclosed.

Get started today.

PharmaChem Investor is your all-in-one solution for making strategic decisions, and driving innovation in the dynamic world of pharmaceuticals.

We notice you're using a small screen...

PharmaChem Investor is designed and optimised best for desktop devices and large screens, to make the most of all of the data available. We recommend accessing the site on a desktop device.

Logout